Hemoglobin Lepore-beta-thalassemia syndrome: A Patient Guide
At a Glance
Hemoglobin Lepore-beta-thalassemia syndrome is an inherited blood disorder that can cause mild or severe anemia. Genetic testing distinguishes the syndrome from the usually mild trait, while transfusions, iron checks, and iron-removing medicines can help protect the heart and liver.
Hearing you have a rare blood condition can be overwhelming, especially when the name itself is complex. Hemoglobin Lepore (Hb Lepore) is a rare blood disorder that occupies a middle ground in the world of hematology. It is categorized as both a structural variant—meaning the makeup of the hemoglobin is unusual—and a form of thalassemia, because the body cannot produce enough of it to prevent anemia [1][2].
This dual nature is caused by a specific genetic event called a delta-beta fusion, where two neighboring genes undergo an unequal crossover during reproduction, creating a single “hybrid” instruction manual [3]. Because this hybrid gene is much less efficient at making the beta-globin protein than a healthy gene, the result is a reduction in functional hemoglobin and a variable degree of anemia that closely mimics standard beta-thalassemia [2][4]. (Note: Bracketed codes like [1] refer to the specific published medical literature that supports these facts.)
The impact of Hb Lepore on your daily life depends heavily on your specific genotype, creating a wide spectrum of severity. Most people have the Hb Lepore trait, which means they carry only one copy of the fusion gene alongside one healthy beta-globin gene [5]. For these individuals, the condition is usually mild—they may have no symptoms or only mild anemia, and it may only be discovered during a routine blood test that shows slightly smaller red blood cells (microcytosis) [3].
However, when a person inherits two copies of the Hb Lepore gene, or inherits one Hb Lepore gene along with a beta-thalassemia mutation, they develop Hemoglobin Lepore-beta-thalassemia syndrome [1]. The severity of the syndrome must be assessed individually; it ranges from a moderate anemia that rarely requires intervention (non-transfusion-dependent thalassemia) to severe chronic anemia that requires regular medical intervention (transfusion-dependent thalassemia) [6][7].
For those living with the syndrome, management is built on three essential pillars: managing anemia, managing iron, and consistent monitoring. Patients with a severe phenotype require regular blood transfusions to provide the healthy red blood cells their bodies cannot make, while those with a milder form may only need blood during specific stressful events like a severe illness or pregnancy [8][7]. Because both the disease itself and the transfusions used to treat it can cause iron to build up in the heart and liver, patients may need medications called chelators to remove this excess iron and prevent organ damage [9][10]. Never start iron supplements or chelation without explicit instructions from your hematologist.
Living successfully with Hb Lepore means establishing a long-term relationship with a specialized care team. Because the condition is rare, it can sometimes be misdiagnosed as simple iron deficiency or standard beta-thalassemia [4]. Specialized molecular testing and individualized check-ups are the best tools for ensuring that your treatment stays ahead of potential complications like bone thinning or heart strain [10][11]. With modern management, including advanced iron monitoring and newer therapies, patients with the syndrome can proactively manage their health and protect their vital organs [10][12].
In this guide
6 chapters
Understanding Hemoglobin Lepore-Beta-Thalassemia Syndrome
Learn how hemoglobin Lepore-beta-thalassemia syndrome affects blood counts, symptoms, genetic types, transfusion needs, diagnosis, and iron-overload monitoring.
Confirming Your Diagnosis: Labs and Pathology for Hb Lepore
Learn how Hb Lepore is confirmed through CBC, hemoglobin analysis, iron studies, specialized genetic testing, and parental testing, including common pitfalls.
Managing the Syndrome: Treatment Strategies for Hb Lepore
Learn how Hb Lepore treatment is tailored to how it affects your body, including transfusions, medicines, iron monitoring, stem cell and gene therapy options.
The Balancing Act: Iron Overload and Chelation Therapy
Learn how Hemoglobin Lepore-beta-thalassemia causes iron overload, how ferritin and MRI assess risk, and how chelation therapy protects your heart and liver.
Recognizing Red Flags: Managing Complications of Hb Lepore
Learn which Hb Lepore complications require emergency care, including spinal EMH, asplenia fever, heart and lung symptoms, and blood-clot warning signs.
Life with Hb Lepore: Long-Term Surveillance and Wellness
Learn how Hb Lepore syndrome affects long-term health, including iron, bone, thyroid, diabetes, pregnancy, emotional wellness, and personalized follow-up care.
Common questions in this guide
What is Hemoglobin Lepore-beta-thalassemia syndrome?
How is the Hb Lepore trait different from the syndrome?
How is Hb Lepore diagnosed?
Will I need regular blood transfusions?
Why are iron levels monitored in this condition?
Should I take iron supplements if I have Hb Lepore anemia?
How can I plan long-term care for Hb Lepore syndrome?
Get notified when new evidence is published on Hemoglobin Lepore-beta-thalassemia syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Homozygous Hemoglobin Lepore: A Rare Condition Seen in a Bangladeshi Family.
Aziz MA, Khan WA, Das SA, Banu B
Mymensingh medical journal : MMJ 2021; (30(4)):1172-1176.
PMID: 34605493 - 2
Biochemical and Molecular Analysis of the Hb Lepore Boston Washington in a Syrian Homozygous Child.
Pirastru M, Manca L, Trova S, Mereu P
BioMed research international 2017; (2017()):1261972 doi:10.1155/2017/1261972.
PMID: 28553644 - 3
Homozygous Lepore Syndrome: A case report.
Bhusal A, Bhandari S, Seth T, Sah RP
Annals of medicine and surgery (2012) 2022; (80()):104168 doi:10.1016/j.amsu.2022.104168.
PMID: 36045803 - 4
Molecular characterization of similar Hb Lepore Boston-Washington in four Chinese families using third generation sequencing.
Zhuang J, Zhang N, Zheng Y, et al.
Scientific reports 2024; (14(1)):9966 doi:10.1038/s41598-024-60604-7.
PMID: 38693200 - 5
Rare occurrence of hemoglobin Lepore variant in a Palestinian patient: a case report and brief literature review.
Asees MY, Shrateh ON, Jobran AWM, Assi AS
Annals of medicine and surgery (2012) 2023; (85(10)):5219-5222 doi:10.1097/MS9.0000000000001212.
PMID: 37811104 - 6
Molecular and clinical analysis of haemoglobin Lepore in Campania, a region of Southern Italy.
Ricchi P, Ammirabile M, Spasiano A, et al.
Hematology (Amsterdam, Netherlands) 2017; (22(7)):437-443 doi:10.1080/10245332.2017.1289304.
PMID: 28218017 - 7
β-Thalassemia Intermedia Caused by Compound Heterozygosity for Hb Lepore-Hollandia and β-Thalassemia is Rare in the Indian Population.
Sreedharanunni S, Chhabra S, Hira JK, et al.
Hemoglobin 2015; (39(5)):362-5 doi:10.3109/03630269.2015.1064004.
PMID: 26291970 - 8
Alpha- and Beta-thalassemia: Rapid Evidence Review.
Baird DC, Batten SH, Sparks SK
American family physician 2022; (105(3)):272-280.
PMID: 35289581 - 9
Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.
Pinto VM, Forni GL
International journal of molecular sciences 2020; (21(22)) doi:10.3390/ijms21228771.
PMID: 33233561 - 10
Increasing prevalence of thalassemia in America: Implications for primary care.
Sayani FA, Kwiatkowski JL
Annals of medicine 2015; (47(7)):592-604 doi:10.3109/07853890.2015.1091942.
PMID: 26541064 - 11
Endocrine dysfunction in homozygous beta-thalassemia: An underrecognized and undertreated consequence of prolonged survival.
Savvidis C, Ilias I
World journal of clinical cases 2025; (13(24)):107612 doi:10.12998/wjcc.v13.i24.107612.
PMID: 40862198 - 12
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD, Viprakasit V, Taher AT, et al.
The New England journal of medicine 2020; (382(13)):1219-1231 doi:10.1056/NEJMoa1910182.
PMID: 32212518
This page is for informational purposes only and does not constitute medical advice. A hematologist should interpret your genetic results and guide decisions about transfusions, chelation, and iron monitoring.